December, 2016: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2016

December 28, 2016

New Patents Issued Across Multiple Geographies in US, Japan and Canada

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2016) BioAegis Therapeutics announces that
during 2016 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infectious disease, neurological disease and renal failure. The plasma gelsolin portfolio now includes more than 20 issued patents and many pending applications.

December, 2016: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2016

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

EVENTS

May 23, 2023: Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

COMPANY DETAILS

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US